Chemotherapy with HPMA Conjugate with pH-Controlled Release of Doxorubicin Exhibits Reduced In Vivo Toxicity and Induces Anti-Tumor Immunity

摘要

An HPMA conjugate with pH-controlled release of doxorubicin was tested for in vitro and in vivo toxicity and efficacy. The conjugate has ten times higher LD50 than the free drug and exhibits outstanding efficacy in eradicating a growing tumor. Moreover, if given in an appropriate dosage, the treatment induces anti-tumor immunity.